Skip to main content
. Author manuscript; available in PMC: 2016 Mar 1.
Published in final edited form as: Neuropharmacology. 2014 Nov 1;90:33–41. doi: 10.1016/j.neuropharm.2014.10.017

Figure 2.

Figure 2

Effects of prenatal exposure to kynurenine on levels of KYNA in the PFC throughout development. KYNA levels (mean ± SEM) are presented for ED21 fetuses on the left Y-axis and for PD2 and PD56-80 offspring on the right Y-axis. Exposure to kynurenine (100 mg/day; EKYN) raised brain KYNA near the end of treatment on ED21 (ECON: n = 8; EKYN: n = 8). There was no difference at PD2 (ECON: n = 8; EKYN: n = 8) yet increased KYNA levels re-appeared as EKYNs reached PD56 (ECON: n = 8; EKYN: n = 8). * P <0.05, *** P < 0.001 vs. ECON.